Purpose To evaluate the effects of pirfenidone nanoparticles on corneal re-epithelialization and scarring, major clinical challenges after alkali burn. Methods Effect of pirfenidone on collagen I and α-smooth muscle actin (α-SMA) synthesis by TGFβ induced primary corneal fibroblast cells was evaluated by immunoblotting and immunocytochemistry. Pirfenidone loaded poly (lactide-co-glycolide) (PLGA) nanoparticles were prepared, characterized and their cellular entry was examined in primary corneal fibroblast cells by fluorescence microscopy. Alkali burn was induced in one eye of Sprague Dawley rats followed by daily topical treatment with free pirfenidone, pirfenidone nanoparticles or vehicle. Corneal re-epithelialization was assessed daily by flourescein dye test; absence of stained area indicated complete re-epithelialization and the time for complete re-epithelialization was determined. Corneal haze was assessed daily for 7 days under slit lamp microscope and graded using a standard method. After 7 days, collagen I deposition in the superficial layer of cornea was examined by immunohistochemistry. Results Pirfenidone prevented (P<0.05) increase in TGF β induced collagen I and α-SMA synthesis by corneal fibroblasts in a dose dependent manner. Pirfenidone could be loaded successfully within PLGA nanoparticles, which entered the corneal fibroblasts within 5 minutes. Pirfenidone nanoparticles but not free pirfenidone significantly (P<0.05) reduced collagen I level, corneal haze and the time for corneal re-epithelialization following alkali burn. Conclusion Pirfenidone decreases collagen synthesis and prevents myofibroblast formation. Pirfenidone nanoparticles improve corneal wound healing and prevent fibrosis. Pirfenidone nanoparticles are of potential value in treating corneal chemical burns and other corneal fibrotic diseases.
References
[1]
Whitcher JP, Srinivasan M, Upadhyay MP (2001) Corneal Blindness: a global perspective. Bull W H O. 79: 214–221.
[2]
McGwin G Jr, Xie A, Owsley C (2005) Rate of eye injury in the United States. Arch Ophthalmol 123: 970–976.
[3]
Wagoner MD (1997) Chemical injuries of the eye: current concepts in pathophysiology and therapy. Surv Ophthalmol 41: 275–313.
[4]
Saika S (2004) TGF-beta signal transduction in corneal wound healing as a therapeutic target. Cornea 23: S25–S30.
[5]
Zieske JD, Hutcheon AE, Guo X, Chung EH, Joyce NC (2001) TGF-beta receptor types I and II are differentially expressed during corneal epithelial wound repair. Invest Ophthalmol Vis Sci 42: 1465–1471.
[6]
Jester JV, Moller-Pedersen T, Huang J, Sax CM, Kays WT, et al. (1999) The cellular basis of corneal transparency: evidence for ‘corneal crystallins’. J Cell Sci 112: 613–622.
[7]
Lee BS, Margolin SB, Nowak RA (1998) Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab 83: 219–223.
[8]
Hewitson TD, Kelynack KJ, Tait MG, Martic M, Jones CL, et al. (2001) Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 14: 453–460.
[9]
Di Sario A, Bendia E, Svegliati BG, Ridolfi F, Casini A, et al. (2002) Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol 37: 584–591.
[10]
Iyer SN, Gurujeyalakshmi G, Giri SN (1999) Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 291: 367–373.
[11]
Raghu G, Johnson WC, Lockhart D, Mageto Y (1999) Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 159: 1061–1069.
[12]
Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, et al. (2005) Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171: 1040–1047.
[13]
Kim H, Choi YH, Park SJ, Lee SY, Kim SJ, et al. (2010) Antifibrotic effect of Pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels. Invest Ophthalmol Vis Sci 51: 3061–3066.
[14]
Zhong H, Sun G, Lin X, Wu K, Yu M (2011) Evaluation of Pirfenidone as a New Postoperative Anti-scarring Agent in Experimental Glaucoma Surgery. Invest Ophthalmol Vis Sci 52: 3136–42.
[15]
Choi K, Lee K, Ryu S-W, Im M, Kook KH, et al. (2012) Pirfenidone inhibits transforming growth factor-β1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19. Molecular Vision 18: 1010–1020.
[16]
Sun G, Lin X, Zhong H, Yang Y, Qiu X, et al. (2011) Pharmacokinetics of pirfenidone after topical administration in rabbit eye. Molecular Vision 17: 2191–2196.
[17]
Trivedi R, Redente EF, Thakur A, Riches DW, Kompella UB (2012) Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology 23: 505101 doi:10.1088/0957-4484/23/50/505101.
[18]
Guha R, Chowdhury S, Palui H, Mishra A, Basak S, et al.. (2013) Doxorubicin-loaded MePEG-PCL nanoparticles for prevention of posterior capsular opacification. Nanomedicine (Epub ahead of print) 1–14. doi:10.2217/NNM.12.175.
[19]
Fantes FE, Hanna KD, Waring GO 3rd, Pouliquen Y, Thompson KP, et al (1990) Wound healing after excimer laser keratomileusis (photorefractive keratectomy) in monkeys. Arch Ophthalmol 108: 665–675.
[20]
Jester JV, Barry PA, Lind GJ, Petroll WM, Garana R, et al. (1994) Corneal keratocytes: in situ and in vitro organization of cytoskeletal contractile proteins. Invest Ophthalmol Vis Sci 35: 730–743.
[21]
Muller LJ, Pels L, Vrensen GF (1995) Novel aspects of the ultrastructural organization of human corneal keratocytes. Invest Ophthalmol Vis Sci 36: 2557–2567.
[22]
Zieske JD, Guimaraes SR, Hutcheon AE (2001) Kinetics of keratocyte proliferation in response to epithelial debridement. Exp Eye Res 72: 33–39.
[23]
Hassell JR, Birk DE (2010) The molecular basis of corneal transparency. Experimental Eye Research 91: 326–335.
[24]
Shi Q, Liu X, Bai Y, Cui C, Li J, et al. (2011) In Vitro Effects of Pirfenidone on Cardiac Fibroblasts: Proliferation, Myofibroblast Differentiation, Migration and Cytokine Secretion. PLoS ONE 6(11): e28134 doi:10.1371/journal.pone.0028134.
[25]
Hisatomi K, Mukae H, Sakamoto N, Ishimatsu Y, Kakugawa T, et al. (2012) Pirfenidone inhibits TGF-β1-induced overexpression of collagen type I and heat shock protein 47 in A549 cells. BMC Pulmonary Medicine 12: 24 doi:10.1186/1471-2466-12-24.
[26]
Yang H, Tyagi P, Kadam RS, Holden CA, Kompella UB (2012) Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS Nano 6: 7595–606.
[27]
Seoane J (2006) Escaping from the TGFb anti-proliferative control. Carcinogenesis 27: 2148–2156.
[28]
Haber M, Cao Z, Panjwani N, Bedenice D, Li WW, et al. (2003) Effects of growth factors (EGF, PDGF-BB and TGF-beta 1) on cultured equine epithelial cells and keratocytes: implications for wound healing. Vet Ophthalmol 6: 211–7.
